Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Summary Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical problem. Using acute myelogenous leukemia (AML) patient-derived xenograft (PDX) models of acquired resistance to BCL-2 (venetoclax) and MCL-1 (S63845) antagonists, we identify common principles of resistance and persistent vulnerabilities to overcome resistance. BH3 mimetic resistance is characterized by decreased mitochondrial apoptotic priming as measured by BH3 profiling, both in PDX models and human clinical samples, due to alterations in BCL-2 family proteins that vary among cases, but not to acquired mutations in leukemia genes. BCL-2 inhibition drives sequestered pro-apoptotic proteins to MCL-1 and vice versa, explaining why in vivo combinations of BCL-2 and MCL-1 antagonists are more effective when concurrent rather than sequential. Finally, drug-induced mitochondrial priming measured by dynamic BH3 profiling (DBP) identifies drugs that are persistently active in BH3 mimetic resistant myeloblasts, including FLT-3 inhibitors and SMAC mimetics. eTOC blurb Bhatt et al. demonstrate that resistance to BCL-2 and MCL-1 antagonists emerges via selection for reduced mitochondrial apoptotic priming. Rapid measurements of drug-induced apoptotic signaling measured by dynamic BH3 profiling identifies targeted agents with in vivo efficacy. BCL-2 and MCL-1 antagonist combinations overcome resistance to either single agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
Salmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences
Soneson, C., Love, M. I., & Robinson, M. D. (2015) · F1000Research · doi:10.12688/f1000research.7563.1 · Cited by 3,929
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Self-citationCerto, M., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S. A., & Letai, A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,288
Self-citationKonopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
Self-citationThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Pollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778
Wei, A. H., Montesinos, P., Ivanov, V., DiNardo, C. D., Novak, J., Laribi, K., Kim, I., Stevens, D. A., Fiedler, W., Pagoni, M., et al. (2020) · Blood · doi:10.1182/blood.2020004856 · Cited by 763
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Di Veroli, G. Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 736
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
Self-citationWei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
DiNardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., et al. (2020) · Blood · doi:10.1182/blood.2019003988 · Cited by 679
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
Del Gaizo Moore, V., Brown, J. R., Certo, M., Love, T. M., Novina, C. D., & Letai, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 608
Self-citationDeng, J., Carlson, N., Takeyama, K., Dal Cin, P., Shipp, M., & Letai, A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.001 · Cited by 513
Self-citationTron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L. H., Chiarparin, E., Cidado, J., Embrey, K. J., Gangl, E., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 490
Waterhouse, N. J., Goldstein, J. C., von Ahsen, O., Schuler, M., Newmeyer, D. D., & Green, D. R. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.2.319 · Cited by 451
Blombery, P., Anderson, M. A., Gong, J.-N., Thijssen, R., Birkinshaw, R. W., Thompson, E. R., Teh, C. E., Nguyen, T., Xu, Z., Flensburg, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1119 · Cited by 434
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 379
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378
Self-citationThe TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Nechiporuk, T., Kurtz, S. E., Nikolova, O., Liu, T., Jones, C. L., D'Alessandro, A., Culp-Hill, R., d'Almeida, A., Joshi, S. K., Rosenberg, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0125 · Cited by 378
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361
Self-citationAcquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Yecies, D., Carlson, N. E., Deng, J., & Letai, A. (2010) · Blood · doi:10.1182/blood-2009-07-233304 · Cited by 360
Self-citationTargeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment
Chen, X., Glytsou, C., Zhou, H., Narang, S., Reyna, D. E., Lopez, A., Sakellaropoulos, T., Gong, Y., Kloetgen, A., Yap, Y. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0117 · Cited by 348
Vo, T.-T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348
Self-citationThe Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295
Self-citationCidado, J., Boiko, S., Proia, T., Ferguson, D., Criscione, S. W., San Martin, M., Pop-Damkov, P., Su, N., Roamio Franklin, V. N., Sekhar Reddy Chilamakuri, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1853 · Cited by 288
Self-citationDeletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
Wang, X., Bathina, M., Lynch, J., Koss, B., Calabrese, C., Frase, S., Schuetz, J. D., Rehg, J. E., & Opferman, J. T. (2013) · Genes & Development · doi:10.1101/gad.215855.113 · Cited by 279
Chonghaile, T. N., Roderick, J. E., Glenfield, C., Ryan, J., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Wood, B., DeAngelo, D. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0353 · Cited by 275
Self-citationSarosiek, K. A., Chi, X., Bachman, J. A., Sims, J. J., Montero, J., Patel, L., Flanagan, A., Andrews, D. W., Sorger, P., & Letai, A. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.048 · Cited by 247
Self-citationTakahashi, S. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-13 · Cited by 241 · cited 6×
“FLT3 signaling can potentially propagate via three distinct downstream proteins, STAT5, MAPK and PI3K/ AKT(Takahashi, 2011).”
BackgroundInfluentialCytochrome c is released in a single step during apoptosis
Goldstein, J. C., Muñoz-Pinedo, C., Ricci, J.-E., Adams, S. R., Kelekar, A., Schuler, M., Tsien, R. Y., & Green, D. R. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401596 · Cited by 228
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
Del Gaizo Moore, V., Schlis, K. D., Sallan, S. E., Armstrong, S. A., & Letai, A. (2008) · Blood · doi:10.1182/blood-2007-06-098012 · Cited by 223
Self-citationSharon, D., Cathelin, S., Mirali, S., Di Trani, J. M., Yanofsky, D. J., Keon, K. A., Rubinstein, J. L., Schimmer, A. D., Ketela, T., & Chan, S. M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2863 · Cited by 217
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Montero, J., Stephansky, J., Cai, T., Griffin, G. K., Cabal-Hierro, L., Togami, K., Hogdal, L. J., Galinsky, I., Morgan, E. A., Aster, J. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0999 · Cited by 212
Self-citationVenetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
Tausch, E., Close, W., Dolnik, A., Bloehdorn, J., Chyla, B., Bullinger, L., Döhner, H., Mertens, D., & Stilgenbauer, S. (2019) · Haematologica · doi:10.3324/haematol.2019.222588 · Cited by 210
Kluk, M. J., Lindsley, R. C., Aster, J. C., Lindeman, N. I., Szeto, D., Hall, D., & Kuo, F. C. (2016) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.02.003 · Cited by 178
BCL-2 inhibition in AML: an unexpected bonus?
Konopleva, M., & Letai, A. (2018) · Blood · doi:10.1182/blood-2018-03-828269 · Cited by 164
Self-citationXenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data
Kluin, R. J. C., Kemper, K., Kuilman, T., de Ruiter, J. R., Iyer, V., Forment, J. V., Cornelissen-Steijger, P., de Rink, I., ter Brugge, P., Song, J.-Y., et al. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2353-5 · Cited by 162
Condon, S. M., Mitsuuchi, Y., Deng, Y., LaPorte, M. G., Rippin, S. R., Haimowitz, T., Alexander, M. D., Kumar, P. T., Hendi, M. S., Lee, Y.-H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500176w · Cited by 152
Matulis, S. M., Gupta, V. A., Nooka, A. K., Hollen, H. V., Kaufman, J. L., Lonial, S., & Boise, L. (2015) · Leukemia · doi:10.1038/leu.2015.350 · Cited by 141
Morales, A. A., Kurtoglu, M., Matulis, S. M., Liu, J., Siefker, D., Gutman, D. M., Kaufman, J. L., Lee, K. P., Lonial, S., & Boise, L. H. (2011) · Blood · doi:10.1182/blood-2011-01-327197 · Cited by 134
Ryan, J., Montero, J., Rocco, J., & Letai, A. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0107 · Cited by 133
Self-citationMitochondrial functions during cell death, a complex (I–V) dilemma
Ricci, J., Waterhouse, N. J., & Green, D. R. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401225 · Cited by 121
Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
Roca-Portoles, A., Rodriguez-Blanco, G., Sumpton, D., Cloix, C., Mullin, M., Mackay, G. M., O’Neill, K., Lemgruber, L., Luo, X., & Tait, S. W. G. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02867-2 · Cited by 100
Kale, J., Kutuk, O., Brito, G. C., Andrews, T. S., Leber, B., Letai, A., & Andrews, D. W. (2018) · EMBO reports · doi:10.15252/embr.201745235 · Cited by 99
Self-citationContribution of Bcl-2 Phosphorylation to Bak Binding and Drug Resistance
Dai, H., Ding, H., Meng, X. W., Lee, S.-H., Schneider, P. A., & Kaufmann, S. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0940 · Cited by 98
Nangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0277 · Cited by 94
MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts
Brunelle, J. K., Ryan, J., Yecies, D., Opferman, J. T., & Letai, A. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200904049 · Cited by 87
Self-citationWaterhouse, N. J., Sedelies, K. A., Sutton, V. R., Pinkoski, M. J., Thia, K. Y. T., Johnstone, R. W., Bird, P. I., Green, D. R., & Trapani, J. A. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401772 · Cited by 64
Cited by
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Targeting MCL-1 protein to treat cancer: opportunities and challenges
Tantawy, S. I., Timofeeva, N., Sarkar, A., & Gandhi, V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1226289 · Cited by 90
BH3 Mimetics in Hematologic Malignancies
Klener, P., Sovilj, D., Renesova, N., & Andera, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810157 · Cited by 31
Metadata
- Authors
- Bhatt, S., Pioso, M. S., Olesinski, E. A., Yilma, B., Ryan, J. A., Mashaka, T., Leutz, B., Adamia, S., Zhu, H., Kuang, Y., Mogili, A., Louissaint, A., Bohl, S. R., Kim, A. S., Mehta, A. K., Sanghavi, S., Wang, Y., Morris, E., Halilovic, E., Paweletz, C. P., Weinstock, D. M., Garcia, J. S., & Letai, A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 38
- Issue
- 6
- Pages
- 872-890.e6
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3098856610
- Cited by
- 185
- References
- 58
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.